United States: Venture Capital

On December 17, 2025, the U.S. Food and Drug Administration (FDA) issued a request for information (RFI) on a proposal designed to help the FDA engage more directly with innovative, venture-backed companies focused on biotechnology, medical devices, AI, and regulatory technology.

Agreenculture, a France-based startup, will expand production and commercial availability of its automation kits following a $7 million Series A raise.

On December 11, the U.S. House of Representatives passed H.R. 3383, the Incentivizing New Ventures and Economic Strength Through Capital Formation Act (the "INVEST Act") on a bipartisan vote of 302 to 123.

Your portfolio companies are innovating at breakneck speed, but is your compliance infrastructure keeping pace? In this edition of our Inside Litigation series, partner Arthur Luk discusses how AI and emerging technologies...

On October 2, 2025, the National Venture Capital Association (NVCA) released it's most recent updates to its model legal documents to reflect recent legal developments, market practices and regulatory priorities.

Our client spotlight in this edition is on Conductive Ventures, a Palo Alto–based venture capital firm that manages $450 million in capital across three funds.

This year's Venture Capital Report offers a detailed review of the US venture capital market, including a breakdown of venture financing activity by state, and analyzes key trends shaping the year ahead.

On July 4, 2025, the One Big Beautiful Bill Act (the "OBBBA") was signed into law. The OBBBA made a number of significant changes to the Internal Revenue Code of 1986, as amended...

Choosing the right legal structure is one of the first and most important decisions a founder faces. Setting up a corporation, a limited liability company, or any other legal governance structure affects taxation, ownership, and investor readiness. While there is no one-size-fits-all answer, there are well-established trade-offs founders should consider.